Clinical trial · Interventional
Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma
A Randomized, Double-blind, Parallel Group Study to Compare the Pharmacodynamics/Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Moderate Persistent Asthma
NCT01103037CI-TRIAL-00048971terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Terminated by sponsor
Summary
Brief summary (as posted)
This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Asthma | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| QAV680 | Drug | — | UNRESOLVED |
| QAV680 Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- QAV680
- interventionNames
- Drug: QAV680
- type
- PLACEBO_COMPARATOR
- label
- QAV680 Placebo
- interventionNames
- Drug: QAV680 Placebo
Primary outcomes (1)
- measure
- Change in Forced Expiratory Volume in one second (FEV1) as measured by Spirometry
- timeFrame
- 28 days
Secondary outcomes (5)
- measure
- FEV1 assessments at various timepoints including time of peak drug concentration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with moderate persistent asthma Exclusion Criteria: * Smokers * Any significant disease or illness, other than asthma Other protocol-defined inclusion/exclusion criteria may apply
References
Publications (0)
Data not yet available
No reference posted for this study.